CZC-8004

CAS No. 916603-07-1

CZC-8004( CZC 8004 | CZC8004 | Dianilinopyrimidine-01 )

Catalog No. M16584 CAS No. 916603-07-1

CZC-8004 (CZC8004, Dianilinopyrimidine-01) is a pan-specific kinase inhibitor that binds to a broad range of tyrosine kinases.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 93 In Stock
5MG 85 In Stock
10MG 140 In Stock
25MG 297 In Stock
50MG 435 In Stock
100MG 626 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    CZC-8004
  • Note
    Research use only, not for human use.
  • Brief Description
    CZC-8004 (CZC8004, Dianilinopyrimidine-01) is a pan-specific kinase inhibitor that binds to a broad range of tyrosine kinases.
  • Description
    CZC-8004 (CZC8004, Dianilinopyrimidine-01) is a pan-specific kinase inhibitor that binds to a broad range of tyrosine kinases, including ABL, BTK, FAK, FER, JAK1, SRC, SYK, TEC, TNK1, TYK2, and YES at low micromolar concentrations.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    CZC 8004 | CZC8004 | Dianilinopyrimidine-01
  • Pathway
    Angiogenesis
  • Target
    Bcr-Abl
  • Recptor
    Bcr-Abl
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    916603-07-1
  • Formula Weight
    309.3
  • Molecular Formula
    C17H16FN5
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : 77.5 mg/mL 250.53 mM
  • SMILES
    C1=CC=C(C=C1)NC2=NC(=NC=C2F)NC3=CC=C(C=C3)CN
  • Chemical Name
    N2-?[4-?(aminomethyl)?phenyl]?-?5-?fluoro-?N4-?phenyl-2,?4-?pyrimidinediamine

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Klutchko SR, et al. J Med Chem. 1998 Aug 13;41(17):3276-92.
molnova catalog
related products
  • PF-06651481-00

    PF-06651481-00 (Bosutinib Isomer I) is a Bosutinib analog and a Bcr-Abl inhibitor.

  • CHMFL-ABL-039

    CHMFL-ABL-039 is a type II native ABL kinase and drug-resistant V299L mutant BCR-ABL inhibitor (IC50s: 7.9 nM and 27.9 nM) used in the research of chronic myeloid leukemia.

  • Adaphostin

    Adaphostin is a p210Bcr/Abl tyrosine kinase inhibitor with IC50 of 14 μM.